# Program10 External Blockers Report
**CyberCom Platform — Release 2**  
**Date:** 2026-06-29  
**Classification:** Confidential — Internal Use Only  
**Roles:** CIO, CCO, CISO, CMIO, Release Manager

---

## Purpose

This report catalogs all external dependencies that cannot be resolved by software engineering. These items must be tracked and resolved before full commercial production launch. They do not block pilot deployment under hypercare.

---

## Critical Blockers (Block Specific Features)

### BLOCKER-01: Drug Interaction Database License

| Attribute | Detail |
|-----------|--------|
| **Blocker ID** | BLOCKER-01 |
| **Priority** | CRITICAL |
| **Blocked Features** | All pharmacy functionality; drug-drug, drug-allergy, drug-pregnancy interaction checking |
| **Description** | CyberCom's `InteractionRule` model holds interaction rules that must be sourced from a licensed clinical drug database. CyberCom does not include proprietary drug content. |
| **Required Action** | License Micromedex (IBM), FDB (First Databank), or equivalent drug interaction database. Populate `InteractionRule` table from licensed source. |
| **Owner** | CIO + CCO |
| **Estimated Lead Time** | 4–8 weeks (contract + integration) |
| **Pilot Impact** | Pharmacy module must be disabled for pilot until resolved. All other modules unaffected. |

### BLOCKER-02: External Penetration Testing

| Attribute | Detail |
|-----------|--------|
| **Blocker ID** | BLOCKER-02 |
| **Priority** | CRITICAL |
| **Blocked Features** | Full commercial production launch |
| **Description** | Annual penetration testing by qualified external security firm is required for healthcare platform compliance. Not yet initiated. |
| **Required Action** | Engage qualified penetration testing firm. Schedule full-scope test (API, infrastructure, auth, tenant isolation). Remediate critical/high findings. |
| **Owner** | CISO |
| **Estimated Lead Time** | 4–6 weeks (engagement + testing + remediation) |
| **Pilot Impact** | Does not block hypercare pilot. Blocks commercial production. |

---

## High Priority (Block Enterprise Sales / Compliance)

### BLOCKER-03: SOC 2 Type II Audit

| Attribute | Detail |
|-----------|--------|
| **Blocker ID** | BLOCKER-03 |
| **Priority** | HIGH |
| **Blocked** | Enterprise/government customers; SLA commitments |
| **Required Action** | Engage SOC 2 auditor. Target: Q4 2026. |
| **Owner** | CCO |
| **Lead Time** | 3–6 months (observation period + audit) |

### BLOCKER-04: IEC 62304 Medical Device Classification

| Attribute | Detail |
|-----------|--------|
| **Blocker ID** | BLOCKER-04 |
| **Priority** | HIGH |
| **Blocked** | Medical device regulatory filing in all markets |
| **Required Action** | Formally classify CyberCom under IEC 62304. Document SDLC, risk management (ISO 14971), SaMD classification. |
| **Owner** | Quality Manager |
| **Lead Time** | 2–4 months |

### BLOCKER-05: External Clinical Validation

| Attribute | Detail |
|-----------|--------|
| **Blocker ID** | BLOCKER-05 |
| **Priority** | HIGH |
| **Blocked** | Clinical workflow sign-off; pharmacy sign-off |
| **Required Action** | Licensed physicians and pharmacists must validate clinical workflows against real patient scenarios. Sign-off required from CMIO and Chief Pharmacist. |
| **Owner** | CMIO + Chief Pharmacist |
| **Lead Time** | 2–4 weeks |

---

## Medium Priority (Market-Specific)

### BLOCKER-06: Jordan MOH / JFDA Registration

| Attribute | Detail |
|-----------|--------|
| **Priority** | MEDIUM |
| **Blocked** | Commercial operation in Jordan |
| **Required Action** | File product registration with Jordan Ministry of Health and Jordan Food and Drug Administration |
| **Owner** | CCO |
| **Lead Time** | 3–6 months |

### BLOCKER-07: Saudi Arabia SFDA + NDMO Filing

| Attribute | Detail |
|-----------|--------|
| **Priority** | MEDIUM |
| **Blocked** | Commercial operation in Saudi Arabia |
| **Required Action** | SFDA digital health product notification + NDMO PDPL privacy registration |
| **Owner** | CCO |
| **Lead Time** | 2–4 months |

### BLOCKER-08: UAE MOHAP Notification

| Attribute | Detail |
|-----------|--------|
| **Priority** | MEDIUM |
| **Blocked** | Commercial operation in UAE |
| **Required Action** | Ministry of Health and Prevention notification for digital health platform |
| **Owner** | CCO |
| **Lead Time** | 1–3 months |

### BLOCKER-09: FHIR National IG Conformance Testing

| Attribute | Detail |
|-----------|--------|
| **Priority** | MEDIUM |
| **Blocked** | National health exchange integration |
| **Required Action** | Test FHIR implementation against each market's national IG (e.g., Saudi Digital Health Authority IG, UAE Malaffi IG) |
| **Owner** | CTO |
| **Lead Time** | 2–4 weeks per market |

### BLOCKER-10: DPO Appointment (GDPR)

| Attribute | Detail |
|-----------|--------|
| **Priority** | MEDIUM |
| **Blocked** | GDPR compliance for EU customers |
| **Required Action** | Appoint Data Protection Officer per GDPR Article 37 |
| **Owner** | Legal / CCO |
| **Lead Time** | 2–4 weeks |

---

## Blocker Tracking Dashboard

| ID | Description | Priority | Owner | ETA | Status |
|----|-------------|----------|-------|-----|--------|
| BLOCKER-01 | Drug DB License | CRITICAL | CIO/CCO | TBD | ⛔ OPEN |
| BLOCKER-02 | Pen Testing | CRITICAL | CISO | TBD | ⛔ OPEN |
| BLOCKER-03 | SOC 2 Type II | HIGH | CCO | Q4 2026 | ⛔ OPEN |
| BLOCKER-04 | IEC 62304 | HIGH | Quality | TBD | ⛔ OPEN |
| BLOCKER-05 | Clinical Validation | HIGH | CMIO | TBD | ⛔ OPEN |
| BLOCKER-06 | Jordan Filing | MEDIUM | CCO | TBD | ⛔ OPEN |
| BLOCKER-07 | Saudi Filing | MEDIUM | CCO | TBD | ⛔ OPEN |
| BLOCKER-08 | UAE Filing | MEDIUM | CCO | TBD | ⛔ OPEN |
| BLOCKER-09 | FHIR IG Testing | MEDIUM | CTO | TBD | ⛔ OPEN |
| BLOCKER-10 | DPO (GDPR) | MEDIUM | Legal | TBD | ⛔ OPEN |

---

## What Is NOT a Blocker

The following items are sometimes raised as concerns but are **not software blockers**:

- ✅ Authentication architecture (OAuth 2.1 / Keycloak 24) — implemented
- ✅ MFA enforcement — implemented and configurable
- ✅ Tenant isolation — implemented and tested
- ✅ Audit trail immutability — implemented (hash chain)
- ✅ Drug interaction engine (software) — implemented; blocked on data license
- ✅ FHIR R4 endpoint — implemented
- ✅ Encryption architecture — implemented (TLS + Vault)
- ✅ Rate limiting — implemented
- ✅ Break glass access — implemented with dual-approval + audit

---

## Summary

**Software Engineering: COMPLETE — All features implemented and tested.**  
**Production Launch: GATED on BLOCKER-01 (drug DB) and BLOCKER-02 (pen test).**  
**Pilot Under Hypercare: AUTHORIZED (non-pharmacy features).**
